Tyrosine kinase inhibitorFDA-approvedSecond-line
Erlotinib
How it works
Blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— EGFR-mutated
Efficacy
Studies show that patients with EGFR-mutated non-small cell lung cancer who received Erlotinib had a response rate of approximately 70%.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Gemcitabine, Dasatinib, and Erlotinib in Treating Advanced Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| New Study Compares Cancer Treatments for Lung Cancer Patients | Lung Cancer | meta-analysis | Osimertinib resulted in significantly longer overall survival compared to erlotinib-based regimens (HR for OS vs. erlotinib: 1.59, 95% CI 1.09-2.31). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.